← Back to Search

Lipid-lowering agent

Milk Polar Lipids for Abdominal Obesity

Phase < 1
Recruiting
Research Sponsored by University of Connecticut
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged 40 to 70 years
Be older than 18 years old
Must not have
Taking medications which primarily affect blood clotting (e.g., warfarin)
Taking anti-inflammatory medications (e.g., corticosteroids)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks

Summary

This trial looks at how drinking milk affects heart health and metabolic diseases like diabetes.

Who is the study for?
This trial is for adults aged 40 to 70 with high LDL cholesterol (bad cholesterol) and a large waistline, indicating abdominal obesity. It's not suitable for individuals with gallbladder, thyroid, gut diseases, autoimmune or chronic inflammatory conditions, diabetes, recent antibiotic use, milk allergies/intolerances, or those on certain medications like statins.
What is being tested?
The study tests if consuming a dairy powder rich in milk polar lipids daily can improve heart health and reduce risk factors associated with heart disease in people with high cholesterol and abdominal obesity.
What are the potential side effects?
Potential side effects are not detailed but may include reactions typical of dairy consumption such as digestive discomfort especially for those who might have undiagnosed lactose intolerance or sensitivity to dairy components.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 40 and 70 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am taking medication that affects blood clotting.
Select...
I am currently taking anti-inflammatory medications.
Select...
I have scleroderma.
Select...
I am taking medication to lower my cholesterol.
Select...
I have diabetes.
Select...
I have had a stroke.
Select...
I have a blood clotting disorder.
Select...
I have heart disease.
Select...
I have kidney disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from Baseline Serum LDL Cholesterol at 8 weeks

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MPL-rich dairy powderExperimental Treatment1 Intervention
Daily consumption of 50 g of dairy powder containing 6.5 g MPL for 8 weeks.
Group II: Control dairy powderPlacebo Group1 Intervention
Daily consumption of 50 g of dairy powder containing \<0.1 g MPL for 8 weeks

Find a Location

Who is running the clinical trial?

Dairy Management Inc.Industry Sponsor
20 Previous Clinical Trials
2,446 Total Patients Enrolled
4 Trials studying Dyslipidemia
789 Patients Enrolled for Dyslipidemia
University of ConnecticutLead Sponsor
192 Previous Clinical Trials
160,750 Total Patients Enrolled

Media Library

Milk Polar Lipid-Rich Dairy Powder (Lipid-lowering agent) Clinical Trial Eligibility Overview. Trial Name: NCT05700916 — Phase < 1
Dyslipidemia Research Study Groups: MPL-rich dairy powder, Control dairy powder
Dyslipidemia Clinical Trial 2023: Milk Polar Lipid-Rich Dairy Powder Highlights & Side Effects. Trial Name: NCT05700916 — Phase < 1
Milk Polar Lipid-Rich Dairy Powder (Lipid-lowering agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05700916 — Phase < 1
~57 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top